title: Fatal combined immune hemolytic anemia after double cord blood transplantation in imatinib-resistant CML.
authors.forename: M
authors.initials: M
authors.lastname: Rokicka
authors.forename: J
authors.initials: J
authors.lastname: Styczynski
authors.forename: B
authors.initials: B
authors.lastname: Michalewska
authors.forename: T
authors.initials: T
authors.lastname: Torosian
authors.forename: A
authors.initials: A
authors.lastname: Tomaszewska
authors.forename: A
authors.initials: A
authors.lastname: Gronkowska
authors.forename: M
authors.initials: M
authors.lastname: Pogorzala
authors.forename: M
authors.initials: M
authors.lastname: Wysocki
authors.forename: M
authors.initials: M
authors.lastname: Lakomy
authors.forename: W
authors.initials: W
authors.lastname: Wiktor-Jedrzejczak
mesh_terms: D000743:Anemia, Hemolytic / Q000150:complications / Q000276:immunology*; D000744:Anemia, Hemolytic, Autoimmune / Q000209:etiology*; D000888:Antibodies, Anti-Idiotypic / Q000097:blood; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects*; D016572:Cyclosporine / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D017809:Fatal Outcome; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D000068877:Imatinib Mesylate; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015466:Leukemia, Myeloid, Chronic-Phase / Q000150:complications / Q000628:therapy; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D013156:Splenectomy; D065227:Transfusion Reaction; D019172:Transplantation Conditioning; D055815:Young Adult
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000970:Antineoplastic Agents; D001549:Benzamides; D007166:Immunosuppressive Agents; D010879:Piperazines; D011743:Pyrimidines; D016572:Cyclosporine; D000068877:Imatinib Mesylate